COVID-19 transmission graph

Coronavirus: WHO declares COVID 19 a pandemic. Prevention | FAQs | COVID-19 portal

URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer

NB:Did you know one coronavirus patient can infect 59,000 others if nothing is done? Dietary cholesterol may not raise cardiovascular risk! Ketogenic diet


From WikiMD
Jump to navigation Jump to search
Template:Infobox drug/title
Clinical data
Trade namesBeleodaq
[[Regulation of therapeutic goods |Template:Engvar data]]Template:Infobox drug/licence
Template:Infobox drug/pregnancy category
Routes of
Intravenous (IV)
ATC code
Legal status
Legal statusTemplate:Infobox drug/legal status
Pharmacokinetic data
Bioavailability100% (IV)
Protein binding92.9–95.8%[1]
Template:Collapsible list
CAS Number
PubChem CID
PubChem SID
PDB ligand
E number{{#property:P628}}
CompTox Dashboard (EPA)
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaTemplate:Infobox drug/chemical formula
Molar massTemplate:Chem molar mass
3D model (JSmol)
Template:Collapsible list
Template:Collapsible list

Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.[2]

It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.[3]

In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer.[4] Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging.[5] Belinostat has been granted orphan drug and fast track designation by the FDA,[6] and was approved in the US for the use against peripheral T-cell lymphoma on 3 July 2014.[3] It is not approved in Europe as of August 2014.[7]

The approved pharmaceutical formulation is given intravenously.[8]:180 Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1*28 allele.[8]:179 and 181


  1. Script error: No such module "citation/CS1".
  2. Script error: No such module "Citation/CS1".
  3. 3.0 3.1 Script error: No such module "citation/CS1".
  4. Script error: No such module "citation/CS1".
  5. Script error: No such module "citation/CS1".
  6. Script error: No such module "citation/CS1".
  7. Script error: No such module "Citation/CS1".
  8. 8.0 8.1

Template:Intracellular chemotherapeutic agents Template:HDAC inhibitors

W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="">Belinostat</a>

  • Individual results may vary for weight loss from our sponsors.